Voltarra Pharmaceuticals Appoints CEO

mia.burns

Richard P. Becker, Jr. CEO

Newly Formed Lehigh Valley Biotech Introduces Clinical Pipeline at Life Sciences Future

BETHLEHEM, Pa. (November 15, 2013) – Voltarra Pharmaceuticals, Inc. has announced the appointment of Richard P. Becker, Jr. as Chief Executive Officer, bringing 20 years of pharmaceutical leadership experience to the newly formed Lehigh Valley company. Voltarra features a portfolio of early-stage small molecules and late-stage novel clinical compounds for rheumatology, the central nervous system, oncology and immunology, which the company obtained through the acquisitions of IMC Biotechnology and Renascense Pharmaceuticals.

Becker has successfully led large, medium and entrepreneurial companies to substantial growth in fiercely competitive markets. During his career, Becker has assumed progressive commercial leadership roles for Alcon, Merck, Novartis, OSI Pharmaceuticals, Bayer and BASF. He has launched six products, commercially developed three others, built organizations and obtained investor financing as a senior executive. Becker received a Masters of Business Administration from Drexel University and a Bachelor of Pharmacy degree from the Philadelphia College of Pharmacy & Sciences.

In Philadelphia on Nov. 13, Becker introduced Voltarra Pharmaceuticals to potential partners during a presentation at Pennsylvania Bio’s Life Sciences Future. A privately held company based in Bethlehem, Voltarra recently acquired both IMC Biotechnology and Renascense Pharmaceuticals, Lehigh Valley biotech companies with a portfolio targeting life-saving and life-enhancing therapies.

“The Renascense Pharmaceuticals portfolio of novel formulated compounds, including zoledronic acid (ZA), progesterone and curcumin, is designed to overcome current treatment…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS